nodes	percent_of_prediction	percent_of_DWPC	metapath
Paliperidone—HTR2C—Sorafenib—liver cancer	0.183	0.439	CbGbCtD
Paliperidone—CYP3A5—Sorafenib—liver cancer	0.0897	0.215	CbGbCtD
Paliperidone—CYP2D6—Sorafenib—liver cancer	0.055	0.132	CbGbCtD
Paliperidone—CYP3A4—Sorafenib—liver cancer	0.035	0.0837	CbGbCtD
Paliperidone—CYP2D6—Doxorubicin—liver cancer	0.0334	0.0799	CbGbCtD
Paliperidone—CYP3A4—Doxorubicin—liver cancer	0.0212	0.0508	CbGbCtD
Paliperidone—Iloperidone—CYP2E1—liver cancer	0.00174	1	CrCbGaD
Paliperidone—Body temperature increased—Sorafenib—liver cancer	0.000891	0.00207	CcSEcCtD
Paliperidone—Abdominal pain—Sorafenib—liver cancer	0.000891	0.00207	CcSEcCtD
Paliperidone—Eczema—Doxorubicin—liver cancer	0.000873	0.00203	CcSEcCtD
Paliperidone—Hypoglycaemia—Epirubicin—liver cancer	0.000869	0.00202	CcSEcCtD
Paliperidone—Lethargy—Epirubicin—liver cancer	0.000865	0.00201	CcSEcCtD
Paliperidone—Cerebrovascular accident—Epirubicin—liver cancer	0.000865	0.00201	CcSEcCtD
Paliperidone—Osteoarthritis—Epirubicin—liver cancer	0.000848	0.00197	CcSEcCtD
Paliperidone—Pain in extremity—Epirubicin—liver cancer	0.000848	0.00197	CcSEcCtD
Paliperidone—Increased appetite—Doxorubicin—liver cancer	0.000835	0.00194	CcSEcCtD
Paliperidone—Hypersensitivity—Sorafenib—liver cancer	0.000831	0.00193	CcSEcCtD
Paliperidone—Face oedema—Epirubicin—liver cancer	0.000818	0.0019	CcSEcCtD
Paliperidone—Asthenia—Sorafenib—liver cancer	0.000809	0.00188	CcSEcCtD
Paliperidone—Cardiac arrest—Epirubicin—liver cancer	0.000806	0.00187	CcSEcCtD
Paliperidone—Hypoglycaemia—Doxorubicin—liver cancer	0.000804	0.00187	CcSEcCtD
Paliperidone—Lethargy—Doxorubicin—liver cancer	0.000801	0.00186	CcSEcCtD
Paliperidone—Cerebrovascular accident—Doxorubicin—liver cancer	0.000801	0.00186	CcSEcCtD
Paliperidone—Pruritus—Sorafenib—liver cancer	0.000798	0.00185	CcSEcCtD
Paliperidone—Osteoarthritis—Doxorubicin—liver cancer	0.000784	0.00182	CcSEcCtD
Paliperidone—Pain in extremity—Doxorubicin—liver cancer	0.000784	0.00182	CcSEcCtD
Paliperidone—Dry skin—Epirubicin—liver cancer	0.000777	0.0018	CcSEcCtD
Paliperidone—Abdominal pain upper—Epirubicin—liver cancer	0.000774	0.0018	CcSEcCtD
Paliperidone—Orthostatic hypotension—Epirubicin—liver cancer	0.000774	0.0018	CcSEcCtD
Paliperidone—Diarrhoea—Sorafenib—liver cancer	0.000771	0.00179	CcSEcCtD
Paliperidone—Breast disorder—Epirubicin—liver cancer	0.000766	0.00178	CcSEcCtD
Paliperidone—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000763	0.00177	CcSEcCtD
Paliperidone—Nasopharyngitis—Epirubicin—liver cancer	0.000758	0.00176	CcSEcCtD
Paliperidone—Face oedema—Doxorubicin—liver cancer	0.000757	0.00176	CcSEcCtD
Paliperidone—Muscular weakness—Epirubicin—liver cancer	0.000748	0.00174	CcSEcCtD
Paliperidone—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000748	0.00174	CcSEcCtD
Paliperidone—Cardiac arrest—Doxorubicin—liver cancer	0.000746	0.00173	CcSEcCtD
Paliperidone—Dizziness—Sorafenib—liver cancer	0.000746	0.00173	CcSEcCtD
Paliperidone—Influenza—Epirubicin—liver cancer	0.000733	0.0017	CcSEcCtD
Paliperidone—Dysphagia—Epirubicin—liver cancer	0.000733	0.0017	CcSEcCtD
Paliperidone—Dry skin—Doxorubicin—liver cancer	0.000719	0.00167	CcSEcCtD
Paliperidone—Pancreatitis—Epirubicin—liver cancer	0.000718	0.00167	CcSEcCtD
Paliperidone—Vomiting—Sorafenib—liver cancer	0.000717	0.00166	CcSEcCtD
Paliperidone—Orthostatic hypotension—Doxorubicin—liver cancer	0.000716	0.00166	CcSEcCtD
Paliperidone—Abdominal pain upper—Doxorubicin—liver cancer	0.000716	0.00166	CcSEcCtD
Paliperidone—Rash—Sorafenib—liver cancer	0.000711	0.00165	CcSEcCtD
Paliperidone—Dermatitis—Sorafenib—liver cancer	0.00071	0.00165	CcSEcCtD
Paliperidone—Breast disorder—Doxorubicin—liver cancer	0.000709	0.00165	CcSEcCtD
Paliperidone—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000706	0.00164	CcSEcCtD
Paliperidone—Headache—Sorafenib—liver cancer	0.000706	0.00164	CcSEcCtD
Paliperidone—Bronchitis—Epirubicin—liver cancer	0.000705	0.00164	CcSEcCtD
Paliperidone—Nasopharyngitis—Doxorubicin—liver cancer	0.000701	0.00163	CcSEcCtD
Paliperidone—Muscular weakness—Doxorubicin—liver cancer	0.000692	0.00161	CcSEcCtD
Paliperidone—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000692	0.00161	CcSEcCtD
Paliperidone—Dysuria—Epirubicin—liver cancer	0.000685	0.00159	CcSEcCtD
Paliperidone—Neutropenia—Epirubicin—liver cancer	0.000685	0.00159	CcSEcCtD
Paliperidone—Upper respiratory tract infection—Epirubicin—liver cancer	0.000681	0.00158	CcSEcCtD
Paliperidone—Influenza—Doxorubicin—liver cancer	0.000678	0.00157	CcSEcCtD
Paliperidone—Dysphagia—Doxorubicin—liver cancer	0.000678	0.00157	CcSEcCtD
Paliperidone—Pollakiuria—Epirubicin—liver cancer	0.000677	0.00157	CcSEcCtD
Paliperidone—Nausea—Sorafenib—liver cancer	0.00067	0.00156	CcSEcCtD
Paliperidone—Weight increased—Epirubicin—liver cancer	0.000667	0.00155	CcSEcCtD
Paliperidone—Pancreatitis—Doxorubicin—liver cancer	0.000665	0.00154	CcSEcCtD
Paliperidone—Weight decreased—Epirubicin—liver cancer	0.000663	0.00154	CcSEcCtD
Paliperidone—Hyperglycaemia—Epirubicin—liver cancer	0.000661	0.00153	CcSEcCtD
Paliperidone—Pneumonia—Epirubicin—liver cancer	0.000657	0.00153	CcSEcCtD
Paliperidone—Infestation NOS—Epirubicin—liver cancer	0.000653	0.00152	CcSEcCtD
Paliperidone—Infestation—Epirubicin—liver cancer	0.000653	0.00152	CcSEcCtD
Paliperidone—Bronchitis—Doxorubicin—liver cancer	0.000652	0.00151	CcSEcCtD
Paliperidone—Jaundice—Epirubicin—liver cancer	0.000637	0.00148	CcSEcCtD
Paliperidone—Conjunctivitis—Epirubicin—liver cancer	0.000635	0.00147	CcSEcCtD
Paliperidone—Urinary tract infection—Epirubicin—liver cancer	0.000635	0.00147	CcSEcCtD
Paliperidone—Dysuria—Doxorubicin—liver cancer	0.000634	0.00147	CcSEcCtD
Paliperidone—Neutropenia—Doxorubicin—liver cancer	0.000634	0.00147	CcSEcCtD
Paliperidone—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00063	0.00146	CcSEcCtD
Paliperidone—Pollakiuria—Doxorubicin—liver cancer	0.000626	0.00145	CcSEcCtD
Paliperidone—Hepatobiliary disease—Epirubicin—liver cancer	0.000618	0.00143	CcSEcCtD
Paliperidone—Weight increased—Doxorubicin—liver cancer	0.000617	0.00143	CcSEcCtD
Paliperidone—Epistaxis—Epirubicin—liver cancer	0.000616	0.00143	CcSEcCtD
Paliperidone—Weight decreased—Doxorubicin—liver cancer	0.000613	0.00142	CcSEcCtD
Paliperidone—Sinusitis—Epirubicin—liver cancer	0.000613	0.00142	CcSEcCtD
Paliperidone—Hyperglycaemia—Doxorubicin—liver cancer	0.000612	0.00142	CcSEcCtD
Paliperidone—Agranulocytosis—Epirubicin—liver cancer	0.00061	0.00142	CcSEcCtD
Paliperidone—Pneumonia—Doxorubicin—liver cancer	0.000608	0.00141	CcSEcCtD
Paliperidone—Infestation NOS—Doxorubicin—liver cancer	0.000605	0.0014	CcSEcCtD
Paliperidone—Infestation—Doxorubicin—liver cancer	0.000605	0.0014	CcSEcCtD
Paliperidone—Bradycardia—Epirubicin—liver cancer	0.000597	0.00139	CcSEcCtD
Paliperidone—Jaundice—Doxorubicin—liver cancer	0.000589	0.00137	CcSEcCtD
Paliperidone—Rhinitis—Epirubicin—liver cancer	0.000588	0.00137	CcSEcCtD
Paliperidone—Conjunctivitis—Doxorubicin—liver cancer	0.000588	0.00136	CcSEcCtD
Paliperidone—Urinary tract infection—Doxorubicin—liver cancer	0.000588	0.00136	CcSEcCtD
Paliperidone—Hypoaesthesia—Epirubicin—liver cancer	0.000584	0.00136	CcSEcCtD
Paliperidone—Urinary tract disorder—Epirubicin—liver cancer	0.000579	0.00135	CcSEcCtD
Paliperidone—Oedema peripheral—Epirubicin—liver cancer	0.000578	0.00134	CcSEcCtD
Paliperidone—Connective tissue disorder—Epirubicin—liver cancer	0.000576	0.00134	CcSEcCtD
Paliperidone—Urethral disorder—Epirubicin—liver cancer	0.000575	0.00134	CcSEcCtD
Paliperidone—Hepatobiliary disease—Doxorubicin—liver cancer	0.000572	0.00133	CcSEcCtD
Paliperidone—Epistaxis—Doxorubicin—liver cancer	0.00057	0.00132	CcSEcCtD
Paliperidone—Sinusitis—Doxorubicin—liver cancer	0.000567	0.00132	CcSEcCtD
Paliperidone—Agranulocytosis—Doxorubicin—liver cancer	0.000564	0.00131	CcSEcCtD
Paliperidone—Bradycardia—Doxorubicin—liver cancer	0.000552	0.00128	CcSEcCtD
Paliperidone—Eye disorder—Epirubicin—liver cancer	0.000548	0.00127	CcSEcCtD
Paliperidone—Tinnitus—Epirubicin—liver cancer	0.000547	0.00127	CcSEcCtD
Paliperidone—Cardiac disorder—Epirubicin—liver cancer	0.000544	0.00126	CcSEcCtD
Paliperidone—Flushing—Epirubicin—liver cancer	0.000544	0.00126	CcSEcCtD
Paliperidone—Rhinitis—Doxorubicin—liver cancer	0.000544	0.00126	CcSEcCtD
Paliperidone—Hypoaesthesia—Doxorubicin—liver cancer	0.00054	0.00125	CcSEcCtD
Paliperidone—Urinary tract disorder—Doxorubicin—liver cancer	0.000536	0.00124	CcSEcCtD
Paliperidone—Oedema peripheral—Doxorubicin—liver cancer	0.000535	0.00124	CcSEcCtD
Paliperidone—Connective tissue disorder—Doxorubicin—liver cancer	0.000533	0.00124	CcSEcCtD
Paliperidone—Angiopathy—Epirubicin—liver cancer	0.000532	0.00124	CcSEcCtD
Paliperidone—Urethral disorder—Doxorubicin—liver cancer	0.000532	0.00124	CcSEcCtD
Paliperidone—Immune system disorder—Epirubicin—liver cancer	0.00053	0.00123	CcSEcCtD
Paliperidone—Mediastinal disorder—Epirubicin—liver cancer	0.000529	0.00123	CcSEcCtD
Paliperidone—Chills—Epirubicin—liver cancer	0.000526	0.00122	CcSEcCtD
Paliperidone—Alopecia—Epirubicin—liver cancer	0.000518	0.0012	CcSEcCtD
Paliperidone—Mental disorder—Epirubicin—liver cancer	0.000514	0.00119	CcSEcCtD
Paliperidone—Erythema—Epirubicin—liver cancer	0.000511	0.00119	CcSEcCtD
Paliperidone—Malnutrition—Epirubicin—liver cancer	0.000511	0.00119	CcSEcCtD
Paliperidone—Eye disorder—Doxorubicin—liver cancer	0.000507	0.00118	CcSEcCtD
Paliperidone—Tinnitus—Doxorubicin—liver cancer	0.000506	0.00117	CcSEcCtD
Paliperidone—Cardiac disorder—Doxorubicin—liver cancer	0.000504	0.00117	CcSEcCtD
Paliperidone—Flushing—Doxorubicin—liver cancer	0.000504	0.00117	CcSEcCtD
Paliperidone—Flatulence—Epirubicin—liver cancer	0.000503	0.00117	CcSEcCtD
Paliperidone—Tension—Epirubicin—liver cancer	0.000501	0.00116	CcSEcCtD
Paliperidone—Dysgeusia—Epirubicin—liver cancer	0.0005	0.00116	CcSEcCtD
Paliperidone—Nervousness—Epirubicin—liver cancer	0.000496	0.00115	CcSEcCtD
Paliperidone—Back pain—Epirubicin—liver cancer	0.000494	0.00115	CcSEcCtD
Paliperidone—Angiopathy—Doxorubicin—liver cancer	0.000492	0.00114	CcSEcCtD
Paliperidone—Muscle spasms—Epirubicin—liver cancer	0.000491	0.00114	CcSEcCtD
Paliperidone—Immune system disorder—Doxorubicin—liver cancer	0.00049	0.00114	CcSEcCtD
Paliperidone—Mediastinal disorder—Doxorubicin—liver cancer	0.000489	0.00114	CcSEcCtD
Paliperidone—Chills—Doxorubicin—liver cancer	0.000487	0.00113	CcSEcCtD
Paliperidone—Vision blurred—Epirubicin—liver cancer	0.000481	0.00112	CcSEcCtD
Paliperidone—Alopecia—Doxorubicin—liver cancer	0.00048	0.00111	CcSEcCtD
Paliperidone—Mental disorder—Doxorubicin—liver cancer	0.000475	0.0011	CcSEcCtD
Paliperidone—Ill-defined disorder—Epirubicin—liver cancer	0.000474	0.0011	CcSEcCtD
Paliperidone—Malnutrition—Doxorubicin—liver cancer	0.000472	0.0011	CcSEcCtD
Paliperidone—Erythema—Doxorubicin—liver cancer	0.000472	0.0011	CcSEcCtD
Paliperidone—Anaemia—Epirubicin—liver cancer	0.000472	0.0011	CcSEcCtD
Paliperidone—Agitation—Epirubicin—liver cancer	0.000469	0.00109	CcSEcCtD
Paliperidone—Flatulence—Doxorubicin—liver cancer	0.000466	0.00108	CcSEcCtD
Paliperidone—Tension—Doxorubicin—liver cancer	0.000464	0.00108	CcSEcCtD
Paliperidone—Dysgeusia—Doxorubicin—liver cancer	0.000463	0.00107	CcSEcCtD
Paliperidone—Malaise—Epirubicin—liver cancer	0.00046	0.00107	CcSEcCtD
Paliperidone—Nervousness—Doxorubicin—liver cancer	0.000459	0.00107	CcSEcCtD
Paliperidone—Vertigo—Epirubicin—liver cancer	0.000459	0.00107	CcSEcCtD
Paliperidone—Syncope—Epirubicin—liver cancer	0.000458	0.00106	CcSEcCtD
Paliperidone—Leukopenia—Epirubicin—liver cancer	0.000457	0.00106	CcSEcCtD
Paliperidone—Back pain—Doxorubicin—liver cancer	0.000457	0.00106	CcSEcCtD
Paliperidone—Muscle spasms—Doxorubicin—liver cancer	0.000454	0.00105	CcSEcCtD
Paliperidone—Palpitations—Epirubicin—liver cancer	0.000451	0.00105	CcSEcCtD
Paliperidone—Loss of consciousness—Epirubicin—liver cancer	0.000449	0.00104	CcSEcCtD
Paliperidone—Cough—Epirubicin—liver cancer	0.000446	0.00103	CcSEcCtD
Paliperidone—Vision blurred—Doxorubicin—liver cancer	0.000445	0.00103	CcSEcCtD
Paliperidone—Convulsion—Epirubicin—liver cancer	0.000442	0.00103	CcSEcCtD
Paliperidone—Hypertension—Epirubicin—liver cancer	0.000441	0.00102	CcSEcCtD
Paliperidone—Ill-defined disorder—Doxorubicin—liver cancer	0.000438	0.00102	CcSEcCtD
Paliperidone—Anaemia—Doxorubicin—liver cancer	0.000437	0.00101	CcSEcCtD
Paliperidone—Arthralgia—Epirubicin—liver cancer	0.000435	0.00101	CcSEcCtD
Paliperidone—Myalgia—Epirubicin—liver cancer	0.000435	0.00101	CcSEcCtD
Paliperidone—Chest pain—Epirubicin—liver cancer	0.000435	0.00101	CcSEcCtD
Paliperidone—Agitation—Doxorubicin—liver cancer	0.000434	0.00101	CcSEcCtD
Paliperidone—Anxiety—Epirubicin—liver cancer	0.000433	0.00101	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000432	0.001	CcSEcCtD
Paliperidone—Discomfort—Epirubicin—liver cancer	0.000429	0.000997	CcSEcCtD
Paliperidone—Malaise—Doxorubicin—liver cancer	0.000426	0.000989	CcSEcCtD
Paliperidone—Dry mouth—Epirubicin—liver cancer	0.000425	0.000987	CcSEcCtD
Paliperidone—Vertigo—Doxorubicin—liver cancer	0.000424	0.000986	CcSEcCtD
Paliperidone—Syncope—Doxorubicin—liver cancer	0.000424	0.000984	CcSEcCtD
Paliperidone—Leukopenia—Doxorubicin—liver cancer	0.000423	0.000982	CcSEcCtD
Paliperidone—Confusional state—Epirubicin—liver cancer	0.00042	0.000976	CcSEcCtD
Paliperidone—Palpitations—Doxorubicin—liver cancer	0.000417	0.000969	CcSEcCtD
Paliperidone—Anaphylactic shock—Epirubicin—liver cancer	0.000417	0.000968	CcSEcCtD
Paliperidone—Oedema—Epirubicin—liver cancer	0.000417	0.000968	CcSEcCtD
Paliperidone—Loss of consciousness—Doxorubicin—liver cancer	0.000415	0.000964	CcSEcCtD
Paliperidone—Infection—Epirubicin—liver cancer	0.000414	0.000961	CcSEcCtD
Paliperidone—Cough—Doxorubicin—liver cancer	0.000412	0.000957	CcSEcCtD
Paliperidone—Shock—Epirubicin—liver cancer	0.00041	0.000952	CcSEcCtD
Paliperidone—Convulsion—Doxorubicin—liver cancer	0.000409	0.00095	CcSEcCtD
Paliperidone—Nervous system disorder—Epirubicin—liver cancer	0.000409	0.000949	CcSEcCtD
Paliperidone—Thrombocytopenia—Epirubicin—liver cancer	0.000408	0.000947	CcSEcCtD
Paliperidone—Hypertension—Doxorubicin—liver cancer	0.000408	0.000947	CcSEcCtD
Paliperidone—Tachycardia—Epirubicin—liver cancer	0.000407	0.000944	CcSEcCtD
Paliperidone—Skin disorder—Epirubicin—liver cancer	0.000405	0.00094	CcSEcCtD
Paliperidone—Arthralgia—Doxorubicin—liver cancer	0.000402	0.000934	CcSEcCtD
Paliperidone—Chest pain—Doxorubicin—liver cancer	0.000402	0.000934	CcSEcCtD
Paliperidone—Myalgia—Doxorubicin—liver cancer	0.000402	0.000934	CcSEcCtD
Paliperidone—Anxiety—Doxorubicin—liver cancer	0.000401	0.000931	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000399	0.000928	CcSEcCtD
Paliperidone—Discomfort—Doxorubicin—liver cancer	0.000397	0.000923	CcSEcCtD
Paliperidone—Anorexia—Epirubicin—liver cancer	0.000397	0.000922	CcSEcCtD
Paliperidone—Dry mouth—Doxorubicin—liver cancer	0.000393	0.000913	CcSEcCtD
Paliperidone—Hypotension—Epirubicin—liver cancer	0.000389	0.000904	CcSEcCtD
Paliperidone—Confusional state—Doxorubicin—liver cancer	0.000389	0.000903	CcSEcCtD
Paliperidone—Anaphylactic shock—Doxorubicin—liver cancer	0.000386	0.000895	CcSEcCtD
Paliperidone—Oedema—Doxorubicin—liver cancer	0.000386	0.000895	CcSEcCtD
Paliperidone—Infection—Doxorubicin—liver cancer	0.000383	0.000889	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00038	0.000882	CcSEcCtD
Paliperidone—Shock—Doxorubicin—liver cancer	0.000379	0.000881	CcSEcCtD
Paliperidone—Nervous system disorder—Doxorubicin—liver cancer	0.000378	0.000878	CcSEcCtD
Paliperidone—Thrombocytopenia—Doxorubicin—liver cancer	0.000377	0.000877	CcSEcCtD
Paliperidone—Insomnia—Epirubicin—liver cancer	0.000377	0.000875	CcSEcCtD
Paliperidone—Tachycardia—Doxorubicin—liver cancer	0.000376	0.000874	CcSEcCtD
Paliperidone—Skin disorder—Doxorubicin—liver cancer	0.000374	0.00087	CcSEcCtD
Paliperidone—Paraesthesia—Epirubicin—liver cancer	0.000374	0.000869	CcSEcCtD
Paliperidone—Dyspnoea—Epirubicin—liver cancer	0.000371	0.000863	CcSEcCtD
Paliperidone—Somnolence—Epirubicin—liver cancer	0.00037	0.00086	CcSEcCtD
Paliperidone—Anorexia—Doxorubicin—liver cancer	0.000368	0.000853	CcSEcCtD
Paliperidone—Dyspepsia—Epirubicin—liver cancer	0.000367	0.000852	CcSEcCtD
Paliperidone—Decreased appetite—Epirubicin—liver cancer	0.000362	0.000841	CcSEcCtD
Paliperidone—Hypotension—Doxorubicin—liver cancer	0.00036	0.000837	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Epirubicin—liver cancer	0.00036	0.000835	CcSEcCtD
Paliperidone—Fatigue—Epirubicin—liver cancer	0.000359	0.000834	CcSEcCtD
Paliperidone—Constipation—Epirubicin—liver cancer	0.000356	0.000827	CcSEcCtD
Paliperidone—Pain—Epirubicin—liver cancer	0.000356	0.000827	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000351	0.000816	CcSEcCtD
Paliperidone—Insomnia—Doxorubicin—liver cancer	0.000349	0.00081	CcSEcCtD
Paliperidone—Paraesthesia—Doxorubicin—liver cancer	0.000346	0.000804	CcSEcCtD
Paliperidone—Dyspnoea—Doxorubicin—liver cancer	0.000344	0.000798	CcSEcCtD
Paliperidone—Feeling abnormal—Epirubicin—liver cancer	0.000343	0.000797	CcSEcCtD
Paliperidone—Somnolence—Doxorubicin—liver cancer	0.000343	0.000796	CcSEcCtD
Paliperidone—Gastrointestinal pain—Epirubicin—liver cancer	0.000341	0.000791	CcSEcCtD
Paliperidone—Dyspepsia—Doxorubicin—liver cancer	0.000339	0.000788	CcSEcCtD
Paliperidone—Decreased appetite—Doxorubicin—liver cancer	0.000335	0.000778	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000333	0.000773	CcSEcCtD
Paliperidone—Fatigue—Doxorubicin—liver cancer	0.000332	0.000772	CcSEcCtD
Paliperidone—Urticaria—Epirubicin—liver cancer	0.000331	0.000769	CcSEcCtD
Paliperidone—Constipation—Doxorubicin—liver cancer	0.00033	0.000766	CcSEcCtD
Paliperidone—Pain—Doxorubicin—liver cancer	0.00033	0.000766	CcSEcCtD
Paliperidone—Abdominal pain—Epirubicin—liver cancer	0.000329	0.000765	CcSEcCtD
Paliperidone—Body temperature increased—Epirubicin—liver cancer	0.000329	0.000765	CcSEcCtD
Paliperidone—Feeling abnormal—Doxorubicin—liver cancer	0.000318	0.000738	CcSEcCtD
Paliperidone—Gastrointestinal pain—Doxorubicin—liver cancer	0.000315	0.000732	CcSEcCtD
Paliperidone—Hypersensitivity—Epirubicin—liver cancer	0.000307	0.000713	CcSEcCtD
Paliperidone—Urticaria—Doxorubicin—liver cancer	0.000306	0.000711	CcSEcCtD
Paliperidone—Abdominal pain—Doxorubicin—liver cancer	0.000305	0.000708	CcSEcCtD
Paliperidone—Body temperature increased—Doxorubicin—liver cancer	0.000305	0.000708	CcSEcCtD
Paliperidone—Asthenia—Epirubicin—liver cancer	0.000299	0.000694	CcSEcCtD
Paliperidone—Pruritus—Epirubicin—liver cancer	0.000295	0.000685	CcSEcCtD
Paliperidone—Diarrhoea—Epirubicin—liver cancer	0.000285	0.000662	CcSEcCtD
Paliperidone—Hypersensitivity—Doxorubicin—liver cancer	0.000284	0.00066	CcSEcCtD
Paliperidone—Asthenia—Doxorubicin—liver cancer	0.000277	0.000642	CcSEcCtD
Paliperidone—Dizziness—Epirubicin—liver cancer	0.000276	0.00064	CcSEcCtD
Paliperidone—Pruritus—Doxorubicin—liver cancer	0.000273	0.000633	CcSEcCtD
Paliperidone—Vomiting—Epirubicin—liver cancer	0.000265	0.000615	CcSEcCtD
Paliperidone—Diarrhoea—Doxorubicin—liver cancer	0.000264	0.000613	CcSEcCtD
Paliperidone—Rash—Epirubicin—liver cancer	0.000263	0.00061	CcSEcCtD
Paliperidone—Dermatitis—Epirubicin—liver cancer	0.000262	0.00061	CcSEcCtD
Paliperidone—Headache—Epirubicin—liver cancer	0.000261	0.000606	CcSEcCtD
Paliperidone—Dizziness—Doxorubicin—liver cancer	0.000255	0.000592	CcSEcCtD
Paliperidone—Nausea—Epirubicin—liver cancer	0.000248	0.000575	CcSEcCtD
Paliperidone—Vomiting—Doxorubicin—liver cancer	0.000245	0.000569	CcSEcCtD
Paliperidone—Rash—Doxorubicin—liver cancer	0.000243	0.000565	CcSEcCtD
Paliperidone—Dermatitis—Doxorubicin—liver cancer	0.000243	0.000564	CcSEcCtD
Paliperidone—Headache—Doxorubicin—liver cancer	0.000242	0.000561	CcSEcCtD
Paliperidone—Nausea—Doxorubicin—liver cancer	0.000229	0.000532	CcSEcCtD
Paliperidone—HRH1—Signaling Pathways—PIK3CB—liver cancer	1.29e-05	8.61e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—CDKN1A—liver cancer	1.29e-05	8.61e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PIK3CB—liver cancer	1.29e-05	8.61e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—CTNNB1—liver cancer	1.29e-05	8.57e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—KRAS—liver cancer	1.28e-05	8.56e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GOT1—liver cancer	1.28e-05	8.52e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GGT1—liver cancer	1.28e-05	8.52e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CCND1—liver cancer	1.28e-05	8.52e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—JUN—liver cancer	1.28e-05	8.5e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MTOR—liver cancer	1.27e-05	8.45e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PIK3CB—liver cancer	1.27e-05	8.45e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MAPK8—liver cancer	1.27e-05	8.45e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CTNNB1—liver cancer	1.27e-05	8.44e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—AKT1—liver cancer	1.26e-05	8.42e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MMP9—liver cancer	1.26e-05	8.4e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MAPK8—liver cancer	1.26e-05	8.4e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—AKT1—liver cancer	1.26e-05	8.38e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—HRAS—liver cancer	1.26e-05	8.38e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—CDKN1A—liver cancer	1.26e-05	8.37e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—MYC—liver cancer	1.25e-05	8.34e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—TGFB1—liver cancer	1.25e-05	8.32e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MMP9—liver cancer	1.24e-05	8.27e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—HRAS—liver cancer	1.24e-05	8.24e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CDKN1A—liver cancer	1.24e-05	8.24e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—MYC—liver cancer	1.24e-05	8.23e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CDKN1B—liver cancer	1.24e-05	8.23e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—HRAS—liver cancer	1.23e-05	8.22e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—TGFB1—liver cancer	1.23e-05	8.21e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MAPK8—liver cancer	1.23e-05	8.17e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—PIK3CA—liver cancer	1.22e-05	8.17e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—AKT1—liver cancer	1.22e-05	8.15e-05	CbGpPWpGaD
Paliperidone—DRD2—GPCR downstream signaling—AKT1—liver cancer	1.22e-05	8.14e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—PIK3CA—liver cancer	1.22e-05	8.1e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CDKN1B—liver cancer	1.22e-05	8.1e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CDKN1B—liver cancer	1.21e-05	8.08e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—VEGFA—liver cancer	1.21e-05	8.08e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—HRAS—liver cancer	1.21e-05	8.07e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CASP3—liver cancer	1.21e-05	8.07e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IL2—liver cancer	1.21e-05	8.06e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MAPK8—liver cancer	1.21e-05	8.04e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—RAF1—liver cancer	1.21e-05	8.04e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—AKT1—liver cancer	1.2e-05	8.02e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—IL6—liver cancer	1.2e-05	8.02e-05	CbGpPWpGaD
Paliperidone—HTR2A—GPCR downstream signaling—AKT1—liver cancer	1.2e-05	8.01e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—STAT3—liver cancer	1.2e-05	8e-05	CbGpPWpGaD
Paliperidone—HRH1—GPCR downstream signaling—AKT1—liver cancer	1.2e-05	8e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—PIK3CA—liver cancer	1.2e-05	8e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CG—liver cancer	1.2e-05	7.99e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CASP3—liver cancer	1.19e-05	7.94e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CDKN1B—liver cancer	1.19e-05	7.93e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IL2—liver cancer	1.19e-05	7.93e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CASP3—liver cancer	1.19e-05	7.92e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IL2—liver cancer	1.19e-05	7.91e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—TP53—liver cancer	1.19e-05	7.9e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—IL6—liver cancer	1.18e-05	7.89e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—IL6—liver cancer	1.18e-05	7.87e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—PIK3CA—liver cancer	1.18e-05	7.87e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CCND1—liver cancer	1.18e-05	7.85e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MTOR—liver cancer	1.18e-05	7.85e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PIK3CB—liver cancer	1.18e-05	7.85e-05	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—AKT1—liver cancer	1.18e-05	7.85e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—JUN—liver cancer	1.18e-05	7.84e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—VEGFA—liver cancer	1.17e-05	7.8e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CTNNB1—liver cancer	1.17e-05	7.78e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CASP3—liver cancer	1.17e-05	7.77e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IL2—liver cancer	1.16e-05	7.76e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—VEGFA—liver cancer	1.16e-05	7.76e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—TP53—liver cancer	1.16e-05	7.74e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CCND1—liver cancer	1.16e-05	7.73e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—IL6—liver cancer	1.16e-05	7.72e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—STAT3—liver cancer	1.16e-05	7.72e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—JUN—liver cancer	1.16e-05	7.71e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CCND1—liver cancer	1.16e-05	7.71e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—KRAS—liver cancer	1.16e-05	7.71e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PPARG—liver cancer	1.16e-05	7.71e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—JUN—liver cancer	1.15e-05	7.7e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—STAT3—liver cancer	1.15e-05	7.68e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CTNNB1—liver cancer	1.15e-05	7.65e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GSTP1—liver cancer	1.15e-05	7.65e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CTNNB1—liver cancer	1.15e-05	7.64e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MMP9—liver cancer	1.14e-05	7.63e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—TP53—liver cancer	1.14e-05	7.61e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—KRAS—liver cancer	1.14e-05	7.61e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CDKN1A—liver cancer	1.14e-05	7.6e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CCND1—liver cancer	1.14e-05	7.57e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—HRAS—liver cancer	1.13e-05	7.56e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—JUN—liver cancer	1.13e-05	7.55e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—HMOX1—liver cancer	1.13e-05	7.55e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—VEGFA—liver cancer	1.13e-05	7.55e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MMP9—liver cancer	1.13e-05	7.5e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—HRAS—liver cancer	1.12e-05	7.5e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CTNNB1—liver cancer	1.12e-05	7.49e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MMP9—liver cancer	1.12e-05	7.49e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CDKN1A—liver cancer	1.12e-05	7.48e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—STAT3—liver cancer	1.12e-05	7.47e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CDKN1A—liver cancer	1.12e-05	7.46e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MYC—liver cancer	1.12e-05	7.43e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—VEGFA—liver cancer	1.11e-05	7.43e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MAPK8—liver cancer	1.11e-05	7.42e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TGFB1—liver cancer	1.11e-05	7.42e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—HRAS—liver cancer	1.11e-05	7.4e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—AKT1—liver cancer	1.11e-05	7.4e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CDKN1B—liver cancer	1.11e-05	7.37e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—STAT3—liver cancer	1.1e-05	7.35e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MMP9—liver cancer	1.1e-05	7.35e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CDKN1A—liver cancer	1.1e-05	7.32e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MAPK8—liver cancer	1.09e-05	7.3e-05	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—AKT1—liver cancer	1.09e-05	7.29e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MAPK8—liver cancer	1.09e-05	7.28e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—HRAS—liver cancer	1.09e-05	7.28e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—AKT1—liver cancer	1.09e-05	7.28e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—AKT1—liver cancer	1.09e-05	7.26e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—IL6—liver cancer	1.08e-05	7.23e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CASP3—liver cancer	1.08e-05	7.22e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IL2—liver cancer	1.08e-05	7.21e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—IL6—liver cancer	1.08e-05	7.18e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MYC—liver cancer	1.08e-05	7.18e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TGFB1—liver cancer	1.07e-05	7.16e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MAPK8—liver cancer	1.07e-05	7.15e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MYC—liver cancer	1.07e-05	7.14e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—AKT1—liver cancer	1.07e-05	7.13e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TGFB1—liver cancer	1.07e-05	7.12e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—PIK3CA—liver cancer	1.06e-05	7.08e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—IL6—liver cancer	1.06e-05	7.08e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—PIK3CA—liver cancer	1.06e-05	7.05e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GSTM1—liver cancer	1.05e-05	7.03e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CCND1—liver cancer	1.05e-05	7.03e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CD—liver cancer	1.05e-05	7.02e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—JUN—liver cancer	1.05e-05	7.02e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—PIK3CA—liver cancer	1.05e-05	6.99e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—IL6—liver cancer	1.05e-05	6.97e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CTNNB1—liver cancer	1.04e-05	6.96e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MYC—liver cancer	1.04e-05	6.94e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—ALB—liver cancer	1.04e-05	6.93e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TGFB1—liver cancer	1.04e-05	6.93e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—KRAS—liver cancer	1.03e-05	6.87e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—TP53—liver cancer	1.03e-05	6.85e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—VEGFA—liver cancer	1.03e-05	6.85e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MYC—liver cancer	1.03e-05	6.83e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MMP9—liver cancer	1.02e-05	6.83e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TGFB1—liver cancer	1.02e-05	6.82e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CDKN1A—liver cancer	1.02e-05	6.8e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—STAT3—liver cancer	1.02e-05	6.78e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—TP53—liver cancer	1.01e-05	6.76e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—VEGFA—liver cancer	1.01e-05	6.74e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—VEGFA—liver cancer	1.01e-05	6.72e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—STAT3—liver cancer	1e-05	6.67e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—AKT1—liver cancer	1e-05	6.67e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CYP1A1—liver cancer	1e-05	6.67e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—STAT3—liver cancer	9.99e-06	6.66e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MAPK8—liver cancer	9.96e-06	6.64e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—KRAS—liver cancer	9.95e-06	6.63e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—AKT1—liver cancer	9.93e-06	6.62e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—VEGFA—liver cancer	9.9e-06	6.6e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—KRAS—liver cancer	9.89e-06	6.6e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—HRAS—liver cancer	9.83e-06	6.55e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—AKT1—liver cancer	9.8e-06	6.53e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—STAT3—liver cancer	9.8e-06	6.53e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—HRAS—liver cancer	9.7e-06	6.47e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—AKT1—liver cancer	9.64e-06	6.43e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—KRAS—liver cancer	9.62e-06	6.42e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—KRAS—liver cancer	9.47e-06	6.31e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—PIK3CA—liver cancer	9.47e-06	6.31e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MYC—liver cancer	9.45e-06	6.3e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TGFB1—liver cancer	9.43e-06	6.28e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—IL6—liver cancer	9.41e-06	6.27e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—MTHFR—liver cancer	9.32e-06	6.22e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MYC—liver cancer	9.3e-06	6.2e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—IL6—liver cancer	9.28e-06	6.19e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MYC—liver cancer	9.28e-06	6.19e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TGFB1—liver cancer	9.28e-06	6.18e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TGFB1—liver cancer	9.26e-06	6.17e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—VEGFA—liver cancer	9.19e-06	6.13e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CB—liver cancer	9.18e-06	6.12e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TP53—liver cancer	9.16e-06	6.1e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PPARA—liver cancer	9.15e-06	6.1e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—PIK3CA—liver cancer	9.14e-06	6.09e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MYC—liver cancer	9.1e-06	6.07e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—STAT3—liver cancer	9.1e-06	6.07e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—PIK3CA—liver cancer	9.09e-06	6.06e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TGFB1—liver cancer	9.08e-06	6.06e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—PIK3CA—liver cancer	8.84e-06	5.89e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TP53—liver cancer	8.84e-06	5.89e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TP53—liver cancer	8.79e-06	5.86e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—HRAS—liver cancer	8.76e-06	5.84e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—KRAS—liver cancer	8.73e-06	5.82e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—PIK3CA—liver cancer	8.7e-06	5.8e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—AKT1—liver cancer	8.68e-06	5.79e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—AKT1—liver cancer	8.64e-06	5.76e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—KRAS—liver cancer	8.59e-06	5.73e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PIK3CA—liver cancer	8.59e-06	5.73e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—KRAS—liver cancer	8.57e-06	5.72e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—AKT1—liver cancer	8.56e-06	5.71e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TP53—liver cancer	8.55e-06	5.7e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MYC—liver cancer	8.46e-06	5.64e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—HRAS—liver cancer	8.45e-06	5.64e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TGFB1—liver cancer	8.44e-06	5.63e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TP53—liver cancer	8.42e-06	5.61e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—KRAS—liver cancer	8.41e-06	5.61e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—HRAS—liver cancer	8.41e-06	5.61e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—IL6—liver cancer	8.38e-06	5.59e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—HRAS—liver cancer	8.18e-06	5.45e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—IL6—liver cancer	8.09e-06	5.39e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—HRAS—liver cancer	8.05e-06	5.37e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—IL6—liver cancer	8.05e-06	5.37e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PIK3CA—liver cancer	8.02e-06	5.35e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PIK3CA—liver cancer	7.89e-06	5.26e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PIK3CA—liver cancer	7.88e-06	5.25e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PIK3CA—liver cancer	7.87e-06	5.25e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CG—liver cancer	7.83e-06	5.22e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—IL6—liver cancer	7.83e-06	5.22e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—KRAS—liver cancer	7.82e-06	5.21e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TP53—liver cancer	7.76e-06	5.17e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—AKT1—liver cancer	7.73e-06	5.15e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PIK3CA—liver cancer	7.73e-06	5.15e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—IL6—liver cancer	7.71e-06	5.14e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TP53—liver cancer	7.64e-06	5.09e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TP53—liver cancer	7.62e-06	5.08e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PPARG—liver cancer	7.56e-06	5.04e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TP53—liver cancer	7.48e-06	4.98e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—AKT1—liver cancer	7.46e-06	4.98e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—AKT1—liver cancer	7.43e-06	4.95e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—HRAS—liver cancer	7.42e-06	4.95e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—HRAS—liver cancer	7.3e-06	4.87e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—HRAS—liver cancer	7.29e-06	4.86e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—AKT1—liver cancer	7.22e-06	4.82e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PIK3CA—liver cancer	7.18e-06	4.79e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—HRAS—liver cancer	7.15e-06	4.77e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—AKT1—liver cancer	7.11e-06	4.74e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IL6—liver cancer	7.1e-06	4.74e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—AKT1—liver cancer	7.02e-06	4.68e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IL6—liver cancer	6.99e-06	4.66e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IL6—liver cancer	6.97e-06	4.65e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TP53—liver cancer	6.95e-06	4.63e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CD—liver cancer	6.89e-06	4.59e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IL6—liver cancer	6.84e-06	4.56e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ALB—liver cancer	6.8e-06	4.53e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—HRAS—liver cancer	6.64e-06	4.43e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—AKT1—liver cancer	6.55e-06	4.37e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—AKT1—liver cancer	6.45e-06	4.3e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—AKT1—liver cancer	6.43e-06	4.29e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—AKT1—liver cancer	6.43e-06	4.29e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IL6—liver cancer	6.36e-06	4.24e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—AKT1—liver cancer	6.31e-06	4.21e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CB—liver cancer	6e-06	4e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—AKT1—liver cancer	5.87e-06	3.91e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CA—liver cancer	5.6e-06	3.73e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—AKT1—liver cancer	4.57e-06	3.05e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CA—liver cancer	3.66e-06	2.44e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—AKT1—liver cancer	2.99e-06	1.99e-05	CbGpPWpGaD
